Hepion Pharmaceuticals, Inc. (HEPA) Latest Company News

Oct 19, 2026, 12:01 UTC
Hepion Pharmaceuticals said it anticipates filing an IND for GV104 and beginning the path toward a Phase 2 study in 2027.
Source:
- accessnewswire.com
Oct 19, 2026, 12:01 UTC
The FDA’s Division of Psychiatry issued written responses to Gravitas Life Sciences’ pre-IND meeting request for GV104, stating that existing nonclinical and manufacturing data may be cross-referenced and that the planned Phase 2 proof-of-concept design is generally appropriate.
Source:
- accessnewswire.com
Oct 14, 2026, 12:01 UTC
Hepion Pharmaceuticals completed its acquisition of Gravitas Life Sciences, which became a wholly owned subsidiary.
Source:
- accessnewswire.com
- hawaiitelegraph.com
Oct 9, 2026, 20:34 UTC
Hepion Pharmaceuticals appointed Sireesh Appajosyula as chief executive officer, effective October 9, 2026.
Oct 9, 2026, 20:34 UTC
Hepion Pharmaceuticals appointed Gary Stetz as chief financial officer, effective October 9, 2026.
Sep 28, 2026, 10:32 UTC
Hepion Pharmaceuticals, Inc. dismissed Grassi & Co., CPAs, P.C. as its independent auditor and appointed Rosenberg Rich Baker Berman P.A. as its new auditor, effective September 21, 2026.
Aug 27, 2026, 00:00 UTC
Hepion Pharmaceuticals entered into securities purchase agreements to sell 8,000,000 shares of common stock and warrants for 8,000,000 shares at $0.05 per share, raising gross proceeds of $400,000.
Aug 20, 2026, 00:00 UTC
James Liddy was appointed as a director of Hepion Pharmaceuticals, Inc., effective August 19, 2026.
Aug 4, 2026, 00:00 UTC
Hepion Pharmaceuticals, Inc. signed a private placement agreement on August 3, 2026, to issue 61,100,000 shares of common stock and warrants for an additional 61,100,000 shares, raising gross proceeds of $3,055,000.

HEPA

Hepion Pharmaceuticals said it anticipates filing an IND for GV104 and beginning the path toward a Phase 2 study in 2027.

The FDA’s Division of Psychiatry issued written responses to Gravitas Life Sciences’ pre-IND meeting request for GV104, stating that existing nonclinical and manufacturing data may be cross-referenced and that the planned Phase 2 proof-of-concept design is generally appropriate.

Hepion Pharmaceuticals completed its acquisition of Gravitas Life Sciences, which became a wholly owned subsidiary.

Hepion Pharmaceuticals appointed Sireesh Appajosyula as chief executive officer, effective October 9, 2026.

Hepion Pharmaceuticals appointed Gary Stetz as chief financial officer, effective October 9, 2026.

Hepion Pharmaceuticals, Inc. dismissed Grassi & Co., CPAs, P.C. as its independent auditor and appointed Rosenberg Rich Baker Berman P.A. as its new auditor, effective September 21, 2026.

Hepion Pharmaceuticals entered into securities purchase agreements to sell 8,000,000 shares of common stock and warrants for 8,000,000 shares at $0.05 per share, raising gross proceeds of $400,000.

James Liddy was appointed as a director of Hepion Pharmaceuticals, Inc., effective August 19, 2026.

Hepion Pharmaceuticals, Inc. signed a private placement agreement on August 3, 2026, to issue 61,100,000 shares of common stock and warrants for an additional 61,100,000 shares, raising gross proceeds of $3,055,000.